Scott Tarriff (Chairman)
President and CEO, Eagle Pharmaceuticals, Inc.
Scott Tarriff is the founder of Eagle Pharmaceuticals, Inc., a publicly traded company, and has served as President and Chief Executive Officer and as a member of its board of directors since its inception. Mr. Tarriff has grown Eagle Pharmaceuticals from a privately financed pharmaceutical development company to an established, publicly traded, specialty pharmaceutical company. Prior to forming Eagle, Mr. Tarriff held various executive positions at Par Pharmaceutical Companies, Inc., a publicly-traded developer, manufacturer and marketer of specialty pharmaceuticals, including as president and chief executive officer from September 2003 to September 2006, after joining Par in 1998. Mr. Tarriff also served on Par’s board of directors from 2002 to September 2006. Prior to that, Mr. Tarriff held various positions with Bristol-Meyers Squibb, a publicly-traded biopharmaceutical company, including senior director-marketing. Mr. Tarriff has served as a director of Synthetic Biologics, Inc., a publicly-traded biotechnology company, since February 2012 and previously served on the board of directors of Clinical Data, Inc., a publicly-traded pharmaceutical company, from September 2009 to April 2011 when Clinical Data was acquired by Forest Laboratories, Inc. Mr. Tarriff holds a B.S. in marketing from Pennsylvania State University and an M.B.A. from Rider College.
Chris Bowden, M.D.
CHIEF MEDICAL OFFICER, AGIOS PHARMACEUTICALS
Dr. Bowden, an oncology drug development executive with more than 20 years leadership experience including the approval of several cancer medicines, joined Ziopharm’s Board in October 2019. He has been the chief medical officer of Agios Pharmaceuticals since May 2014. Previously, Dr. Bowden was vice president product development oncology, at Genentech for eight years. From 2003 to 2006, he was the executive director for EMEA regions for Bristol-Myers Squibb. Earlier, Dr. Bowden held positions of increasing responsibility in oncology clinical development, at Pharmacia Corporation and Janssen Pharmaceutical. Prior to industry, Dr. Bowden was on the oncology faculty at the University of Virginia Health Science Center. Dr. Bowden received his M.D. from Hahnemann University School of Medicine followed by internal medicine training at Roger Williams Medical Center and the Providence VA Medical Center, Rhode Island. He completed his medical oncology fellowship at the National Cancer Institute Medicine Branch. Dr. Bowden is board certified in internal medicine and medical oncology.
Scott Braunstein, M.D.
Operating Partner, Aisling Capital
Dr. Braunstein is an Operating Partner at Aisling Capital, a leading investment firm. He held leadership roles including Chief Operating Officer, Chief Strategy Officer and Senior Vice President of Strategy at Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the clinical and commercial development of new products utilized in acute patient care. Earlier in his career, Dr. Braunstein held positions in finance at Everpoint Asset Management and J.P. Morgan Asset Management. He began his career as a practicing physician at the Summit Medical Group and as Assistant Clinical Professor at Albert Einstein College of Medicine and for Columbia University Medical Center after completing his training at the New York Hospital/Cornell Medical Center, his research experience at Rockefeller University, and earning his medical degree from the Albert Einstein College of Medicine.
Laurence Cooper, M.D., Ph.D.
Chief Executive Officer, Ziopharm Oncology
Laurence joined Ziopharm Oncology as chief executive officer in 2015 after Ziopharm and Intrexon Corporation together licensed technology for a non-viral approach for genetically modifying T cells from MD Anderson Cancer and the University of Minnesota. This technology is designed to reduce the cost and complexity of genetically modified T cells. Prior to joining Ziopharm, Laurence was a tenured Professor at MD Anderson with joint appointments in the Division of Pediatrics and Department of Immunology. There, he served as Section Chief of Cell Therapy at the Children’s Cancer Hospital and helped lead scientific efforts to develop new treatment approaches which pair genetic engineering with immunotherapies. He remains a visiting scientist at MD Anderson.
Laurence has coauthored dozens of peer-reviewed journal articles, abstracts, and book chapters. He has initiated multiple trials under INDs infusing T cells and NK cells. He obtained his M.D. and Ph.D. degrees at Case Western Reserve University in Cleveland and he completed his training in Pediatric Oncology and Bone Marrow Transplantation at the Fred Hutchinson Cancer Research Center in Seattle.
RETIRED CHIEF OPERATING OFFICER, SCHOLAR ROCK
Mr. Ezickson has been a member of our board since September 2018. He served as chief operating officer and head of corporate development at Scholar Rock Holding Corporation from August 2014 until his retirement in December 2018, where he directed corporate development, operations and administration and execution of corporate strategy for this Cambridge, MA-based clinical-stage biotechnology company. He played a significant role in corporate finance at Scholar Rock, which raised $86 million in its IPO in June 2018. Prior to joining Scholar Rock, Mr. Ezickson served as Executive Vice President and Chief Operating Officer of Aveo Pharmaceuticals, Inc., where he worked from 2003 to July 2013. From 1994 to 2003, he worked at Biogen Inc. in roles that included President of Biogen Canada, Program Executive and Associate General Counsel. Elan holds a B.A. in political science from Yale University and a J.D. from the Columbia University School of Law.
CO-FOUNDER AND CHIEF STRATEGY OFFICER, VINETI
Ms. Hagen, an experienced and entrepreneurial biotechnology operations executive, joined Ziopharm’s Board in June 2019. She is Co-Founder and Chief Strategy Officer of Vineti, a cloud-based software platform company that addresses challenges in data management from order through cell collection, manufacturing, and delivery of personalized treatments such as cell and gene therapies and cancer vaccines. Beginning her career at Immunex Corporation, Ms. Hagen worked for ten years in a range of roles in drug development and operations management. Following Immunex, she served as Senior Vice President of Operations for more than a decade at Dendreon. More recently, she was the Global Chief Operating Officer for SOTIO, a diverse pharmaceutical company specializing in oncology, based in Prague. Ms. Hagen also serves on the board of directors for Vericel, a commercial-stage biopharmaceutical company specializing on cellular therapies for sports medicine and severe burn care markets. She has a B.S. in Cell and Molecular Biology, an M.S. in Bioengineering, and an MBA from the University of Washington.
Chief Financial Officer, KSQ THERAPEUTICS
Mr. Pagán currently serves as chief financial officer of KSQ Therapeutics, a position he has held since April 2019. Prior to KSQ Therapeutics, Mr. Pagán was chief financial officer at Paratek Pharmaceuticals, where he played the leading role in the company’s financial strategy since 2014, during which time it raised well over $500 million from the public markets. Prior to joining Paratek, he was Vice President, Finance at Acceleron Pharma Inc., where he was instrumental in the company’s successful IPO as well as multiple rounds of private and public equity and debt financings. Prior to working at Acceleron, Mr. Pagán served in strategic and financial management roles at Biogen Idec and Bristol-Myers Squibb. Previously, Mr. Pagán was an investment banker in J.P. Morgan’s Healthcare group, and he held a number of pharmaceutical operational roles at Johnson and Johnson. Mr. Pagán received his BSE in chemical engineering from Princeton University and his MBA from Columbia Business School.